Intellia Therapeutics Receives Major Price Target Boost Following Regulatory Clearance

Intellia's Phase 3 ATTR trial resumes, triggering a major analyst upgrade with a 110% price target. The biotech's pipeline advances with a key HAE study readout due in 2026.

A significant reassessment of Intellia Therapeutics is underway after a key clinical trial hold was lifted. Market experts have responded with a substantial upgrade, raising questions about whether the biotech firm can translate this operational milestone into sustained share price appreciation.

Regulatory Hurdle Cleared for Flagship Program

The surge in analyst confidence stems directly from the U.S. Food and Drug Administration (FDA) permitting the resumption of the MAGNITUDE trial. This Phase 3 study, conducted in partnership with Regeneron, is evaluating the investigational therapy, nex-z, for transthyretin amyloidosis (ATTR).

The agency had initially paused the clinical investigation in 2025 following a patient death. The decision to allow the study to proceed indicates that the FDA's immediate safety concerns have been addressed. Market observers continue to monitor the unresolved specifics surrounding the earlier incident, but the clearance nonetheless removes a major obstacle for the company's most advanced asset.

Analyst Action Highlights Substantial Upside

In a direct reaction to the news, Jones Trading upgraded its rating on the gene-editing specialist from "Hold" to "Buy." The firm established a new price target of $29.00 per share. Based on a recent trading level around $13.61, this implies a potential upside of approximately 110 percent.

Equity researchers point to a clear disconnect between the current market valuation and the future potential embedded in Intellia's clinical pipeline. The stock has already demonstrated notable momentum this year, climbing 51 percent since January and recouping some of the losses triggered by prior regulatory challenges.

Pipeline Progress Extends Beyond ATTR

While the ATTR program is back on track, Intellia is also advancing another key candidate. Focus is building on lonvo-z, a potential treatment for hereditary angioedema (HAE), currently in a Phase 3 trial named HAELO.

Top-line data from this study is scheduled for release in mid-2026. These results are considered crucial for demonstrating the efficacy of the company's CRISPR-based platform in late-stage clinical development. The strategic collaboration with Regeneron provides not only financial support but also aids in preparations for the potential future commercialization of these gene therapies.